enGene Therapeutics Inc. - 1781879 - ENGENE THERAPEUTICS INC
Thanks everyone for joining. This is our fireside chat with Engene. My name is David Dai. I'm a biotech analyst here at UBS. I cover mostly oncology and it's a great pleasure to have Ron Cooper, Chief Executive Officer of Engene with us today. Ron, welcome. David, what a pleasure to be here. Thank you for the invitation. Fantastic. So Engene, very interesting story. So maybe Ron can just, you know, from a high level perspective, just helps understand a little more about Engene's story, especially you have a very interesting lead program called Dental Imaging. Tell us more about that. Yeah, so NGIN is a unique company in that our company is focused on non-viral gene therapies. So we have a unique platform called the DDX platform. From that platform, we have product called Dettolimagine voroplasmin, which we're developing for non-muscle invasive bladder cancer. What's exciting about Dettal imaging is a well-advanced asset. We just put out some data very recently. We'll talk about that in a little bit. But this is an asset that we plan to file the BLA by the end of this year, and we expect an approval next year. So what's pretty exciting is that we translated this unique technology, this non-viral gene therapy, into a medicine that we hope to have in the hands of urologists and patients with non-muscular invasive bladder cancer very soon. Got it. Yeah, very interesting. So a non-viral approach towards IRN or NMIBC non-muscle muscle bladder cancer, you know, the space is a little bit crowded, especially given the fact that there's an ontological virus and others. So tell us a little more about this mechanism of this non-viral approach and how is it different from other approaches we're looking at here? Well, it's totally unique, right? And so I think that's what makes it very, very special Because as you've indicated, Dave, there are chemo approaches, there are viral gene therapy approaches, and there are bacterial approaches. We're the only non-viral gene therapy. And what makes dental imaging unique is it's actually a simple plasmid, not an LMP, with three genes in it with our proprietary sugar that's peculated. What's beautiful about that is that these are all readily available ingredients, and they are relatively easy to put together, so we have a very competitive cost of goods. But because it's non-viral, the handling, an aspect of cost of good is handling, shipping, storage. This is non-viral, so it's a lot easier to ship, handle, and store. And what's interesting about our approach is that combination of genes that we use, RIG-I, 2-RIG-I and 1-IL-12, that stimulates both the innate and adaptive immune system. So when people are thinking about managing non-muscle invasive bladder cancer, which we believe is going to be a disease that gets sequenced much like multiple myeloma or others, dental imaging will be unique, it will be a different product within that sequence. Got it. And just on that administration side, you said this is pretty convenient. Tell us a little more about it. Is this similar to BCG where you're doing intravesicular delivery and the handling? Would you expect a physician to use something similar to what they're doing with BCG already? BCG and better. So better. So all of these therapies are intravescular administered. But it's interesting. We recently had a patient at the office talking about BCG therapy, and we kind of take it for granted. But BCGotherapy is an hour and a half dwell time. It's six weeks. It's intense. It has cumulative toxicity with it. The urine bleaching requirements require people two cups of bleach. So when you think about your lifestyle and things, if you're going to restaurants or if you'RE going to concerts or traveling, You're going to lug around all that bleach. When you think about detalimogene, so detalimegene, first of all, is stored in a regular fridge or regular freezer, so the same place where you put your ice cream or where you Put your yogurt. No special handling. Someone just reaches into the fridge, mixes with water. There's no pre-washes or anything like instill, and the patient can go from there. And you see from our recent data that the tolerability profile is really quite impressive. We have the lowest treatment discontinuation rate and treatment interruption rate. So that's really a measure of the tolerabilty. So, in fact, I would argue it's even easier than BCG to use. Got it. So better administration, easier to use BCG, and, you know, off the shelf. Imagine, you just grab it from the fridge and administer it. So, you know, very good. And the data, you know, I think you just, you know, showed some interesting data last week, right? And so help us walk us through that data set. What do we learn from that? Well, we learn that dental imaging is highly efficacious and well-tolerated on top of, you know, the great handling. So if we break it down for the efficacy parameters, all of our efficacy parameters improved since our last update, which is great news. So when you think about it, from an FDA perspective, the primary endpoint is complete response at any time. The dental imaging CR rate moved from 54% to 56%, which puts it right in the middle of the range of approved products. The next thing the FDA looks at is safety and tolerability, as I indicated to you. Even with increased exposures, the profile still holds really strong. And with a very low rate of discontinuations, very low rate of treatment interruptions, really the lowest of all the products. And then from a secondary endpoint perspective, the secondary endpoint is of those 56% of patients, what percentage are still in response 12 months and beyond. And most of the products, the approved products are in the 40s or 50s. Our Kaplan-Meier curve estimates that that'll be 43%, and that jumped up from 25% to 43%. The other measures of durability that are looked at is median duration of action. Again, ours moved from 8.6% to 10.1%. And when you look at the confidence interval, the upper limit has not been reached yet, so there's still some time to get more. And the last parameter, which is somewhat of a durability measure, although it's not in the label and it's not promotable, is the 12-month landmark complete response rate. And that jumped from 13% to 24%. So if you put it all together, all efficacy parameters improved quite significantly. And even with increased exposures, tolerability held. Got it. Got it, very interesting, actually. And so very compelling efficacy profile overall. Now, as I said, the space is getting a little bit crowded, right? Especially we have now a few different approved products. You know, we have most recently products from Johnson & Johnson and Lexo. We have already approved therapies like Adstralogen from, you know, Immunity Bio and Teva and also from Kichuda. So all these are, you now, approved products, how do you view these compared to the profile, of XC Profile compares to, you know, all these other approved therapies? Yeah, I think, first of all, I don't like using the word competitive here, and I don'T like usingthe term this is a small market. These are all complementary medicines. I'm actually the biggest advocate for all of these products. And one of the reasons that I am an advocate, I'd start with a couple of numbers. If you look in the Legend study, 93 of the patients that were eligible that were that said you know would you like you know we think you should have a radical cystectomy said no people don't want their organs removed they don't their bladders removed radical cystctomy that's a big surgery that has eye mortality and their morbidity associated with having an ostomy appliance losing sexual function it's just it's not very good there's a reason that people don'T want to do that so that's the first point The second point is I've been spending a lot of time with patients of late. And when you meet a patient who decides they don't want their bladder removed, they don'T want their bladder removed. They want anything that's available to them. And so what we see is a world going forward of where there will be multiple products being sequenced. That's already happening. But I would also say it's probably happening more in the academic and the academic-like centers. Those centers have the luxury of staff. They have the luxurious of equipment to be able to use some of these newer products. And some of the first-generation products are just difficult to administer. There's a lot of pre-washes. There's special storage. You need BSL-2 hoods. You need to bleach afterwards. So there's a lot that goes around that. So these products are predominantly being used in the academic and academic-like centers. When you think about where most of the patients are, 75% of the patient are in community-like settings. And in these community settings, they have a shortage of staff. They have a storage of equipment. The logistics are really important. And dental imaging represents what I would consider to be a next-generation type product that easily slides into the community practice where there are actually more patients. So that combination of efficacy, of great tolerability, and ease of use, the hurdle rate to use that, I just believe makes it more attractive and actually will unlock the community setting. And I just believe all of these new products are going to be sequenced because people want to keep their bladders. Got it, got it. One thing that you said is very interesting is sequencing. So where along the line of, let's say, first line, second line, third line, do you envision data limiting would be used along that sequencing? Especially since, let us say, a drug will be used in front line, where do you feel data limitting will beused subsequent to that? So the nice thing about dental imaging, unlike any of the other approved products, it can be used if you are a urologist by yourself in Wisconsin, right, or at Sloan Kettering. It's one of the few products that has the ability to be used in all places. I think our feeling is that where most of the patients are in the academic centers, I'm sorry, in the community centers, if you look at a couple other really important data points with dental imaging. So we already talked a little bit about the convenience and the ease of use. But in our recent data update, 91% of the patients respond in the first three months. Only 3% progress. And if you make it to a year, if you get into the maintenance phase, 100% of those patients are durable. So then, getting back to what I said before, if the hurdle rate for using this product is relatively easy, you can get efficacy really quickly, you'll know if it works, and you do no harm, we believe in the community setting, this is a product that gets used very early. Very easy for the doctor to use, fits into the flow. Now, as we get closer to the academic sense, where we still think we're going to get a lot of usage there as well, The academics, what are they getting? They're getting patients that have already been exposed to gemcitabine, already been exposure to something else. They want to try something different. And that's where the fact that we are the only non-viral gene therapy becomes very attractive to them. So we believe the dental limb gene, for where the patients are being initiated earlier, but certainly for some of these patients that are a bit more experienced because it's a non-viral approach and the only one, It'll be something different that, you know, the academics will be interested in as well. Got it. And help us, let me level set the market just a little bit more around, you Know, how big do you envision this market is? You know, because we've seen reports of saying in BCG, unresponsive population, in high-risk NIPC, you're looking at about 25,000 patients, right, from an incident standpoint. But just based on what you say, it seems like if you're going after sequencing, it could be even bigger than that. So it helps to understand a little bit more around where do you feel or do you see the market opportunities for this? Well, I would agree with your estimates, but the estimates range from 25 to 40, right, and beyond. And as big as the whole total population around 125,000. And the reason nobody puts a finger on it is just because what you've described before, it's a dynamic market. It's a growing market. I would say the analogy would be when Revlimid was launched in multiple myeloma, that was roughly a billion-dollar product in the dollar market. Now you add over a dozen products in multiple Myeloma. This is a $20 billion market size. And you see the sequencing through bites and different types of products. I think we're at the dawn of something really great for patients with NMIA-BC and for the urologists, right? So I think 20,000, 25,000 right now is a conservative estimate. With these new products being approved, patients are going to require new medicines. And as I said, even the most potent product, the best ones, 50% of them need another medicine. The key thing here is patients don't progress. It's a 20% over a 10-year time. It's a 20% progression, but they recur. And that's why you need those new medicines like dental imaging. Got it. Yeah, that's really helpful here. Great. And then, you know, since the data you just presented last week is a pivotal study, it's a legend study, and so, you Know, the data actually could be supportive of the filing. And you said that you were actually looking to initiate a BLA filing end of this year and then looking to complete it by early next year. So what are some getting steps before you can actually start filing here? Well, we just recently had a pre-BLA meeting with the FDA, and that went really well. On the basis of that, we've confirmed that we plan to initiate the filing by the end of this year. As you know, there are five modules to be filed. Two are administrative modules. Module three is the manufacturing module. module, and we've completed our FDA PPQ validation batches. The FDA gave us CDRP, so we've had a lot of dialogue on manufacturing, so it's not a throw it over the fence situation. So we feel really good about that module. And what people forget is that's usually the biggest module. That's probably five times the size of the clinical module. Module four is the preclinical module, which we've had done for a while. And then module five is the clinical module. And here, as we shared with our data, most of our patients are through. We have nine more patients to go. So we'll find a mechanism to put those in a little bit later on. So, we're in great shape. We anticipate initiating the filing this year, and we expect an approval in 2027. Got it. And, then, you mentioned that the FDA meeting aligned with the FDA in terms of patient numbers as well, right? And the most recent update, you actually took out five patients from that addressable population. So tell me a little more about why, what's the reason behind those five patients, and why did the FDA allow you to eliminate or exclude those five patient accordingly? Yeah, that's pretty standard, right, so as you finish enrollment of your pivotal program, you have a discussion with the FDA on the statistical analysis plan. It's pretty important in a pre-BLE meeting to align on the efficacy of valuable population because when you're completing Module 5, you need to know what patients are going in there. And so we agreed with the FDA on the major points of the statistical analysis plan, and that resulted in us going from 125 to 120 patients. But these were five patients that didn't really fit the criteria that they put forward on. They either didn't have a follow-up measurement, they either didn'T have adequate BCG, or they didn'T have carcinoma in situ in the right time frame. So that homogenizes the patient population. But this, as you've seen with other products, it's pretty common if you see what they publish and what gets into the label, there usually is a change in five out of 125 which is one of the larger NMIBC databases, is actually quite small. Got it. And as part of this FDA alignment, did FDA agree on what we consider approvable from anytime CR, durability standpoint? What did FDA say in terms of what's the hurdle going to be for these kind of parameters on the efficacy side? Yeah, I hear that word hurdle a lot. I think that's a Wall Street name. The FDA doesn't have hurdles. The FDA, in general, looks at every product on the basis of risk and benefits, right? And in our case, when you think about risk, as I said to you before, lowest treatment interruption rate, lowest discontinuations. If I put dental imaging and put it on your hands, nothing's going to happen. I would never do that, but nothing is going to happened. And so the non-viral approach from a risk perspective is low. And if you look at the primary endpoint, the primary end point, that's what they wait. At 56%, see our rate any time is in the range of other products. And then, as I shared with you, that cluster of durability metrics, our product lasts a reasonable amount of time. So I don't think they would be allowing us to initiate the filing, right? And normally the FDA, if they tell you to file something, they intend to approve that as well. So I would say that we're in pretty good shape. We feel very good about the package. We feel really good about our FDA dialogue. We'll get the filing in this year, and then we look forward to an approval in 2027. Great, great, great. So end of this year initiating the filing, completing it by early next year, and potentially approved next year. So that's actually going to be quite a bit of a catalyst going forward. Have you done any work in terms of the market, assessing the commercial opportunity? what's kind of the commercial work that you've done so far in terms of trying to establish the market yet, engaging with the community physicians so far. Tell us a little bit more around the commercial side, because, you know, launching is soon. Yeah, well, we've been very active. So, you Know, we're delighted that, you Now, our Chief Global Commercialization Officer, Amy Pod, has been with us with quite some time. And we have a terrific head of medical affairs as well. So we've had medical affairs folks on the ground already. We've been doing extensive market research to really understand the customer bases and where the customers are. If you look at the launch pedigree within our organization, you know, Amy has launched multiple products, you know, through her time at Shire, through Estella's. I've launched dozens of products all over the world. In my previous company, we had a product approval launched in the U.S. and in Europe. So I think we feel pretty confident about our launch plans. We're on track in our commercialization efforts, our early efforts. But now that we've had the updated data, which shows improvements in all efficacy parameters and holding from a convenience standpoint, and we will be initiating the filing, it's time to gear up a lot more. So the intensity of what we're doing is going to pick up, as you would expect, as we get closer to launch. Got it. And is there any early feedback from physicians so far, especially in the community setting? You know, did you bring this updated data over to the community physicians and how did they view that? Well, it's interesting you say that because, you know, we put out some interim data earlier in the year that the market did not react very well to. Paradoxically, that very week, we went to the American Urological Association meeting and the doctors were like, oh, this looks great. This is right in range of what we expect. This is a non-viral approach. So even in the data that we had previously, where we were within range from a primary point, but our durability data was immature. We only had five and a half months of follow-up on that. Now that the data has matured, we would expect the commentary to be even better. So we did have a small advisory board earlier before that data came out, and it was like two thumbs up from that. Now that we just put the data out next week, our medical affairs teams are engaging and gaining feedback. And, you know, there's some upcoming meetings as well. So I think in general what we're hearing from urologists is they're just excited to have actual medicines that can help these patients. and the fact that this is a non-viral gene therapy that they can actually use anywhere, anywhere, in a small community practice, in an academic setting, I think they're getting pretty excited about things. The feedback's been terrific. Fantastic. It's great to hear. Great work. And then just kind of for the next seven minutes or so, I'd love to dive into the other aspect of your development, which is you're actually running this surfactant cohort with the limer gene, basically adding a surfactin rinse, right? And, you know, the idea here is, you Know, with the surfactan rinse, you're able to have a better, potentially better penetration of IL-12 expression in the bladder wall. So tell us a little bit more about that. You know, what gives us confidence that this increased expression of IL12 would give rise to better efficacy, anytime CR, and durability standpoint? Well, I think it first starts off with what are we tracking with dental imaging right now? So we're tracking to what we would consider to be potentially best-in-class durability, best-In-class safety and handling, best- In-class cost and goods, and In- class efficacy, right? But we're a company that's trying to do things that are better for patients. So we've always had life cycle management plans in our place. How do we make dental imaging even more convenient and even more efficacious? So we have been looking at surfactant bladder rinses for quite some time. So if you think about it, we think that we can actually boost efficacy but also improve convenience by reducing the dwell time. So what is the basis of belief for that? First of all, if you look at the viral gene therapies, the one approved and the one in development, if you Look at their preclinical models, without a surfactant bladder rinse, you get very little or no transfection at all. You add a surfacant bladder and you improve transfections. What's great about dental imaging with the proprietary DDX formulation that we have, that without a bladder rinse surfactants bladder rinse we get transfected and you can see that. But if you add a surfactant bladder rinse, and we've selected polydocanol, which is an approved product with a lot of data behind it, you get both better depth and breadth of transfection. That's really interesting. And if you look at both our murine models and invalidating NHPs, that's up to 10 times increase in IL-12 expression. So that is really interesting for us. So what we've done is we've started another cohort of patients that are very similar to the pivotal cohort. It's the exact same inclusion-exclusion criteria. And what we're doing is administering a very short bladder. It's five minutes. So you put it in, take it out, same catheter. Then you put dead limb and genome. But then we're cutting the dwell time by 50% as well. So that should give what we hope to provide is a double bonus for patients because we have to remember these are patients who have gone through a lot these are beaten up bladders or already incontinent holding it in is difficult so reduction of 50 percent with the trade-off with just a little extra time with the bladder rinse should net the savings of 25 of 20 25 minutes well we're pleased as we're up and going with this cohort of patients we've cleared the safety run-in which is great first time that we've used polydocanol in the bladder, and so now we're enrolling that, and we're looking forward to providing an update mid-next year with that cohort of patients. Got it, and for that data update in mid-nxt year, could you just help us study a little more around, you know, expectation around the number of patients we should be looking for? Is there any internal bar, you Know, are we looking for, let's say, 10, 15 times better than what we're already seeing with the imaging? What do we think in terms of efficacy? Yeah, so I think first of all, what we're looking for is somewhere around 20-ish patients, mid-next year, six months data, right? I think the other thing that you should be able to see is from a PD perspective, we have dental imaging IL-12, and then we'll have IL- 12 with these patients that have the surfactants. So we hope to show a difference in that. It won't be the same as in the preclinical models where it's up to 10 times increased because we don't want to take people's bladders out and chop them up and look at them. But we'd like to see, from a PD perspective, an increase in IL-12. And then I think the first win for us, so we'd like to See that from a PT perspective. The second thing is if we can have the exact same efficacy and we go down to half the time of dwell time, that would be a win on top of that. And then any extra efficacy we get or extra durability, that Would be a bonus as well. So I think there are multiple wins for us with these surfactant bladderins. Got it. And then the expectation is to have another BLA after, because we want to imagine, you know, the L-imogen will be approved next year, right? And then, the data for cohort two, sorry, the cofactin cohort will probably come a little bit later or around the same time. So, is the expectation to add this top of label without a study, or are you looking to submit another BLE, you now, for the surfactin cohort? Yeah, right now, our current plans is that the surfacin cohort would be an S-BLA. And so it would be a supplementary. You know, I think for us is we're very focused. We're very focussed right now in getting this BLA and very focussed in on getting the approval, very focusse in on building up our commercial capabilities so we can launch this thing successfully. And then, you know, on the back of that strong base to put a supplementar and I think is the strategy that we believe is the most, you now, the most prudent. Got it. Great. And then so for the next 6 to 12 months, maybe just help us understand a little more around what kind of catalysts we should be looking for here, what are the key focus or deliverables you're looking to do? Yeah, so I think this is a catalyst-rich period. I believe that it's only going to get better here. Like as we said, even in May, we just need time, right? So by the end of this year, we expect to initiate the filing. Sometime early next year, the FDA will tell us they've accepted the filing. Mid-2027, we will have the dental imaging plus surfactant cohort. And we expect by the end of next year to have an approval for dental imaging. So as I said, this is a catalyst-rich time frame. And as time goes on, we're going to know more that de-risks what we're doing even more so. So to me, it's a good time now, but it's going to get better over time. Excellent. Great. Ron, this was really good. I'm looking forward to a data-rich 2027 with multiple calluses, including approval and also potentially a date from the sulfractin cohort. David, thanks again. We're pretty excited at NG. The company has existed for a number of years. So to get dental imaging approved and to patients with NMIBC as the only non-viral gene therapy, I think it's going to be a very special year for us. Thank you so much, Ron. Really appreciate it.
- Company
- ENGENE THERAPEUTICS INC
- Keywords
- ENGENE THERAPEUTICS INC